Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B010-A in advanced hepatocellular carcinoma
NCT05070156Phase 1Active, not recruiting
- Sponsor
- Tongji University
- Start
- Oct 2021
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B010-A in hepatocellular carcinoma (HCC), sponsored by Tongji University. Primary endpoint: Treatment-Emergent Adverse Events at 24 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
B010-A
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05070156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070156.